Familial Nasopharyngeal Carcinoma 6

112 J-C. LinTable 9.6. Summary of other serum/plasma biomarkers on the prognosis of nasopharyngeal carcinomaSeries No. of cases Stage Treatment Markers Cutoff Univariate analysisOSLiaw et al. (1997) 118 IV, M0 RT ± Ch LDH >vs.£140 U/l p = 0.008Hong et al. (2001) 111 III–IV NeoCh+RT LDH >vs.£419 U/l –Lee et al. (2005a) 348 III–IV RT ± Ch LDH continous variable –Cheng SH et al.(2006a)630 II–IV RT+Ch LDH ³vs.vs.£460 U/l p = 0.01Chang et al. (2008) 155 I–IV RT ± Ch MIP-3a >vs.vs.